Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Ethinylestradiol + Levonorgestrel + Venetoclax|
Ethinylestradiol is a synthetic derivative of estrogen, which binds to the estrogen receptor complex and has the potential to result in anti-tumor activity (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ethinylestradiol||Ethinyl Estradiol|Diogyn E|Ethinoral|Eticylol||Ethinylestradiol is a synthetic derivative of estrogen, which binds to the estrogen receptor complex and has the potential to result in anti-tumor activity (PMID: 32234928).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119||BCL2 inhibitor 18||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03557619||Phase I||Ethinylestradiol + Levonorgestrel + Venetoclax||A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies||Recruiting|